Cart
sales@molnova.com
Home - Products - Apoptosis - IL Receptor - Vunakizumab

Vunakizumab

CAS No. 1792181-33-9

Vunakizumab( —— )

Catalog No. M36738 CAS No. 1792181-33-9

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 490 In Stock
10MG 787 In Stock
25MG 1169 In Stock
50MG 1535 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    Vunakizumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis .
  • Description
    Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1792181-33-9
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Chunlei Zhang, et al. A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2022 Jul;87(1):95-102.??
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • Pascolizumab

    Pascolizumab (SB-240683) is a humanized monoclonal antibody targeting IL-4, exhibiting asthmatic effects and useful for studying allergic rhinitis.

  • ABzOH

    ABzOH is a benzoic acid derivative, similar in structure to non-steroidal anti-inflammatory drugs such as aspirin, with anti-inflammatory, anti-tumor and anti-proliferative effects.

  • Chrysosplenol D

    Chrysosplenol D, an efflux pump inhibitor that can potentiate the activity of commercially important antibiotics and antimalarials.

Sign In Join Free